a 2016 0018

The invention relates to new isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them.

The present invention relates particularly to compounds of formula (I):

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{b} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix} P_{a} \\ P_{c} \\ P_{c} \end{pmatrix}$$

$$P_{a} = \begin{pmatrix}$$

wherein substituents are as defined in the description of the invention. The compounds of the present invention have pro-apoptotic properties, which enable their use in diseases involving a defect in apoptosis, such as, for example, in the treatment of cancers, autoimmune and immune system diseases.

Claims: 35